FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on ...

Little Green Pharma Ltd. (AU:LGP) has released an update. Little Green Pharma Ltd. is hosting an investor webinar where CEO Paul Long will present the Quarterly Activities Report for September 2024.

This move will significantly enhance the company's ability to advance the use of proteomics as a vital tool for the pharmaceutical and biotech industries. Building on recent strategic initiatives ...

Firebrick Pharma Limited (AU:FRE) has released an update. Firebrick Pharma Limited has made significant strides with its nasal spray, Nasodine, by securing a local manufacturing agreement in the ...

A pharmaceutical body has warned of potential shortages of some medicines in Northern Ireland unless there is a delay to the implementation of the Windsor Framework. The framework is the post ...

Windows is often said to be a highly customizable OS, but most users remain unaware of the wide range of changes they can make. For instance, many wonder if they can change the boot logo in Windows 10 ...

Readers help support Windows Report. We may get a commission if you buy through our links. Windows 11 isn’t known for its customization features, but many are wondering how to change boot logo in ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

The global pharmaceutical industry is growing and offers an attractive opportunity for investors. Well-established pharmaceutical stocks include AbbVie, Eli Lilly, Johnson & Johnson, and Pfizer.

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases. The Danish pharmaceutical company is offering ...